Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The Cardiovascular Risk in Young Finns Study

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 512-515

  Päivä, Hannu ^a   Kähönen, Mika ^b   Lehtimäki, Terho ^a,b   Alfthan, Georg ^c   Viikari, Jorma ^d   Laaksonen, Reijo ^a,e   Hutri Kähönen, Nina ^b   Laitinen, Tomi ^f   Taittonen, Leena ^g   Raitakari, Olli T ^d   Juonala, Markus ^d  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Asymmetric dimethylarginine; Endothelium; Flow mediated dilatation

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; ENDOTHELIUM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULTRASOUND; VASODILATATION;

ADULT; ARGININE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 77957713880     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.041     Document Type: Article

References (15)

1. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358:2127-2128.
2. Zoccali C., Bode-Böger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
3. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006, 38:126-136.
4. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
5. Böger R.H., Bode-Böger S., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
6. Perticone F., Sciacqua A., Maio R., et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005, 46:518-523.
7. Juonala M., Viikari J.S.A., Alfthan G., et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in The Cardiovascular Risk in Young Finns Study. Circulation 2007, 116:1367-1373.
8. Cockcroft D.W., Gault M.H., Cockcroft D.W., et al. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
9. Teerlink T., Nijveldt R.J., de Jong S., et al. Determination of arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002, 303:131-137.
10. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1992, 362:801-809.
11. Ardigo D., Stuehlinger M., Franzini L., et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 2007, 37:263-269.
12. Yasuda S., Miyazaki S., Kanda M., et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006, 27:1159-1165.
13. Cardounel A.J., Xia Y., Zweier J.L. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin. J Biol Chem 2005, 280:7540-7549.
14. Brunini T., Moss M., Siqueira M., et al. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effect of arterial hypertension. Clin Exp Pharmacol Physiol 2004, 31:738-740.
15. Cardounel A.J., Cui H., Samouilov A., et al. Evidence for the pathophysiological role of andogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007, 282:879-887.